[
    [
        {
            "time": "2019-07-30",
            "original_text": "Pre-Market Earnings Report for July 30, 2019: PG, MA, PFE, MRK, LLY, MO, COP, ECL, MMC, HCA, ETN, PEG",
            "features": {
                "keywords": [
                    "Earnings",
                    "Pre-Market",
                    "PFE",
                    "MRK",
                    "LLY"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "consumer goods"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pre-Market Earnings Report for July 30, 2019: PG, MA, PFE, MRK, LLY, MO, COP, ECL, MMC, HCA, ETN, PEG",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-07-30",
            "original_text": "Pfizer to Combine Off-Patent Drug Business With Mylan",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Mylan",
                    "Off-Patent",
                    "Drug",
                    "Business"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pfizer to Combine Off-Patent Drug Business With Mylan",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-07-30",
            "original_text": "Q2 Earnings Preview For Eli Lilly",
            "features": {
                "keywords": [
                    "Q2",
                    "Earnings",
                    "Preview",
                    "Eli Lilly"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Q2 Earnings Preview For Eli Lilly",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-07-30",
            "original_text": "Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up",
            "features": {
                "keywords": [
                    "Sanofi",
                    "Q2",
                    "Earnings",
                    "Dupixent",
                    "EPS"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-07-30",
            "original_text": "Should You Buy Eli Lilly (LLY) Ahead of Earnings?",
            "features": {
                "keywords": [
                    "Buy",
                    "Eli Lilly",
                    "Earnings"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Should You Buy Eli Lilly (LLY) Ahead of Earnings?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-07-30",
            "original_text": "What's in Store for Array BioPharma (ARRY) in Q4 Earnings?",
            "features": {
                "keywords": [
                    "Array BioPharma",
                    "Q4",
                    "Earnings"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "What's in Store for Array BioPharma (ARRY) in Q4 Earnings?",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-07-30",
            "original_text": "Is Eli Lilly (NYSE:LLY) A Risky Investment?",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Risky",
                    "Investment"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Is Eli Lilly (NYSE:LLY) A Risky Investment?",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        }
    ]
]